ABSTRACT
Importance The United States Food & Drug Administration (FDA) passively monitors medical device performance and safety through submitted medical device reports (MDRs) in the Manufacturer and User Facility Device Experience (MAUDE) database. These databases can be analyzed for patterns and novel opportunities for improving patient safety and/or device design.
Objectives The objective of this analysis was to use supervised machine learning to explore patterns in reported adverse events involving cochlear implants.
Design The MDRs for the top three CI manufacturers by volume from January 1st 2009 to August 30th 2019 were retained for the analysis. Natural language processing was used to measure the importance of specific words. Four supervised machine learning algorithms were used to predict which adverse event narrative description pattern corresponded with a specific cochlear implant manufacturer and adverse event type - injury, malfunction, or death.
Setting U.S. government public database.
Participants Adult and pediatric cochlear patients.
Exposure Surgical placement of a cochlear implant.
Main Outcome Measure Machine learning model classification prediction accuracy (% correct predictions).
Results 27,511 adverse events related to cochlear implant devices were submitted to the MAUDE database during the study period. Most adverse events involved patient injury (n = 16,736), followed by device malfunction (n = 10,760), and death (n = 16). Submissions to the database were dominated by Cochlear Corporation (n = 13,897), followed by MedEL (n = 7,125), and Advanced Bionics (n = 6,489). The random forest, linear SVC, naïve Bayes and logistic algorithms were able to predict the specific CI manufacturer based on the adverse event narrative with an average accuracy of 74.8%, 86.0%, 88.5% and 88.6%, respectively.
Conclusions & Relevance Using supervised machine learning algorithms, our classification models were able to predict the CI manufacturer and event type with high accuracy based on patterns in adverse event text descriptions.
Level of evidence 3
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Meeting Submission: This paper was accepted for presentation at the ACI ‘Ci2020’ Annual Meeting, Orlando, Florida, March 18-22.
Manuscript Submission:
Each of the authors indicated above have contributed to, read and approved this manuscript.
FINANCIAL DISCLOSURE: no authors have disclosures related to this manuscript.
CONFLICT DISCLOSURE: no authors have conflicts related to this manuscript.
In consideration of the journal reviewing and editing my submission, the authors undersigned transfers, assigns and otherwise conveys all copyright ownership in the event that such work is published.
Data Availability
The data that support the findings of this study are openly available in the FDA MAUDE database at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm.
